Streetbeat News

INVO

INVO Bioscience, Inc.

https://www.invobio.com

Industry

Medical - Devices

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

INVO BioScience reported a Q2 EPS of $(0.62), an improvement from $(3.06) year-over-year. Revenue increased to $1.826 million from $315,902 YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:08 pm

Merck & Co., Inc. (NYSE:MRK) shares fell 10% after the company reported second-quarter financial results and cut its FY24 adjusted EPS guidance below estimates. Despite beating revenue and EPS estimates, the guidance cut led to a sharp decline. Other stocks such as Imunon, Inc. (NASDAQ:IMNN) and JetBlue Airways Corporation (NASDAQ:JBLU) saw significant gains due to positive news, while QXO, Inc. (NASDAQ:QXO) and VBI Vaccines Inc. (NASDAQ:VBIV) experienced substantial losses.

Portfolio Pulse from Avi Kapoor

July 30, 2024 | 5:53 pm

Pitney Bowes shares surged over 12% in pre-market trading after selling part of its e-commerce business to Stord. Other notable pre-market movers include Cognition Therapeutics, Longeveron, and Abbott Laboratories, among others.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 9:26 am

Invo Bioscience announced that on June 18, 2024, it received a notice from Nasdaq granting its request for continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 8:23 pm

INNO BioScience shares are trading higher after the company reported a year-over-year increase in Q1 EPS results.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:56 am

INVO Bioscience (NASDAQ:INVO) reported a Q1 EPS loss of $(0.42) and sales of $1.58 million, marking a 352.84% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 8:45 pm

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Notable gainers include SINTX Techs (SINT), Petros Pharma (PTPI), and Bluejay Diagnostics (BJDX). Significant losers include Eyenovia (EYEN), Lucy Scientific Discovery (LSDI), and Monte Rosa Therapeutics (GLUE).

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 8:32 pm

INVO Bioscience's short interest has risen by 39.13%, with 17,000 shares sold short, representing 0.64% of its float. This increase in short interest could indicate bearish sentiment among investors. However, INVO's short interest is still lower than its peer group average of 2.05%.

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 8:15 pm

Alibaba Group Holding Limited (NYSE:BABA) shares fell by around 7% following mixed Q1 financial results. Other stocks experienced significant movements, with notable gainers including Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) and losers like Scorpius Holdings, Inc. (NASDAQ:SCPX).

Portfolio Pulse from Avi Kapoor

May 14, 2024 | 5:30 pm

Alcon Inc. shares surged over 10% in pre-market trading due to better-than-expected Q1 earnings, with several other stocks showing significant movement based on recent performance and financial results.

Portfolio Pulse from Avi Kapoor

May 14, 2024 | 12:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.